The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 561-574

  Beatty, Megan N ^a   Blumenthal, Paul D ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Intrauterine contraceptive device; Intrauterine system; Levonorgestrel releasing; Mirena

Indexed keywords

DANAZOL; ESTRADIOL VALERATE PLUS NORGESTREL; GONADORELIN DERIVATIVE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE;

ACNE; ADENOMYOSIS; AMENORRHEA; BREAST CANCER; CARDIOVASCULAR DISEASE; DEEP VEIN THROMBOSIS; DEPRESSION; DEVELOPED COUNTRY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIOSIS; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LIBIDO DISORDER; LUNG EMBOLISM; MENOPAUSAL SYNDROME; MENORRHAGIA; MENSTRUAL IRREGULARITY; MULTIPLE CYCLE TREATMENT; OLIGOMENORRHEA; OVARY CYST; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; WEIGHT GAIN;

EID: 77949470236     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. ESHRE Capri Workshop Group. Intrauterine devices and intrauterine systems. Hum Reprod Update. 2008;14:197-208.
2. d' Arcanges C. Worldwide use of intrauterine devices for contraception. Contraception. 2007;75:S2-S7.
3. Berlex Pharmaceuticals. Mirena® Physician Information. July 2008. Accessed on June 24, 2009. Available from: http://berlex.bayerhealthcare.com/ html/products/pi/Mirena-PI.pdf.
4. Lahteenmaki P, Rauramo I, Backman T. The levonorgestrel intrauterine system in contraception. Steroids. 2000;65:693-697.
5. Sivin I. Another look at the Dalkon Shield: meta-analysis underscores its problems. Contraception. 1993;48:1-12.
6. Shelton J. Risk of clinical pelvic inflammatory disease attributable to an intrauterine device. Lancet. 2001;357(9254):443.
7. Stanback J, Shelton J. Pelvic inflammatory disease attributable to the IUD: modeling risk in West Africa. Contraception. 2008;77: 227-229.
8. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994;49:56-72.
9. Morrison CS, Murphy L, Kwok C, Weiner DH. Identifying appropriate IUD candidates in areas with high prevalence of sexually transmitted infections. Contraception. 2007;75(3):185-192.
10. Veldhuis HM, Vos AG, Lagro-Janssen AL. Complications of the intrauterine device in nulliparous and parous women. Eur J Gen Pract. 2004;10(3):82-87.
11. Lete I, Morales P, de Pablo JL. Use of intrauterine contraceptive devices in nulliparous women: personal experience over a 12-year period. Eur J Contracept Reprod Health Care. 1998;3:190-193.
12. World Health Organization. Intrauterine devices. In: Medical Eligibility Criteria for Contraceptive Use. 3rd edition. Geneva, Switzerland: World Health Organization; 2004.
13. Ng YW, Liang S, Singh K. Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism - a randomized comparative study. Contraception. 2009;79(1):24-28.
14. Kayikcioglu F, Gunes M, Ozdegirmenci O, Haberal A. Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study. Contraception. 2006;73: 528-531.
15. Ng YW, Liang S, Singh K. Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism - a randomized comparative study. Contraception. 2009;79:24-28.
16. World Health Organization. Medical Eligibility Criteria for Contraceptive Use: 2008 Update. 2008. Accessed on May 10, 2009. Available from: http://www.who.int/reproductive-health/publications/mec/mec-update-2008.pdf.
17. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (April 2004): the levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. J Fam Plann Reprod Health Care. 2004; 30:99-108.
18. Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database Syst Rev. 2001;2: CD001327.
19. Hubacher D, Reyes V, Lillo S, Zepeda A, Chen PL, Croxatto H. Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. Am J Obstet Gynecol. 2006;195:1272-1277.
20. Oloto EJ, Bromham DR, Murty JA. Pain and discomfort perception at IUD insertion. Effect of short-duration, low-volume, intracervical application of 2% lignocaine gel (Instillagel™) - a preliminary study. Br J Fam Plann. 1997;22:177-180.
21. Sääv I, Aronsson A, Marions L, Stephansson O, Gemzell-Danielsson K. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Hum Reprod. 2007;22:2647-2652.
22. Thonneau PF, Almont T. Contraceptive efficacy of intrauterine devices. Am J Obstet Gynecol. 2008;198:248-253.
23. Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception. 1991;44: 473-480.
24. Díaz J, Faúndes A, Díaz M, Marchi N. Evaluation of the clinical performance of a levonorgestrel-releasing IUD, up to seven years of use, in Campinas, Brazil. Contraception. 1993;47:169-175.
25. Rönnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand. 1999;78:716-721.
26. Grimes DA, Lopez LM, Manion C, Schulz KF. Cochrane systematic reviews of IUD trials: lessons learned. Contraception. 2007; 75(6 Suppl):S55-S59.
27. Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years' follow-up. Contraception. 2003;68(1): 31-34.
28. Hayes JL, Cwiak C, Goedken P, Zieman M. A pilot clinical trial of ultrasound-guided postplacental insertion of a levonorgestrel intrauterine device. Contraception. 2007;76:292-296.
29. Eroǧlu K, Akkuzu G, Vural G, et al. Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. Contraception. 2006;74:376-381.
30. Milsom I. The levonorgestrel-releasing intrauterine system as an alternative to hysterectomy in perimenopausal women. Contraception. 2007;75(6 Suppl):S152-S154.
31. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkilä A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol. 1998;105(6):592-598.
32. Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet. 2001;357(9252):273-277.
33. Blumenthal P, Trussell J, Sing R, et al. Cost-effectiveness of treatments for dysfunctional uterine bleeding in women who need contraception. Contraception. 2006;74(3):249-258.
34. Lethaby A, Cooke I, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005;4:CD002126.
35. Bulun SE. Endometriosis. N Engl J Med. 2009;360:268-279.
36. Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005;20:1993-1998.
37. Petta CA, Ferriani RA, Abrao MS, et al. A 3-year follow-up of women with endometriosis and pelvic pain users of the levonorgestrel-releasing intrauterine system. Eur J Obstet Gynecol Reprod Biol. 2009;143:128-129.
38. Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod. 2005;20:789-793.
39. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril. 2003;80:305-309.
40. Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril. 1997;68:426-429.
41. Fong Y, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception. 1999;60:173-175.
42. Cho S, Nam A, Kim H, et al. Clinical effects of the levonorgestrelreleasing intrauterine device in patients with adenomosis. Am J Obstet Gynecol. 2008;198:373.e1-e7.
43. Varma R, Soneja H, Bhatia K, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia - a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008;139:169-175.
44. Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol. 2006;125:259-264.
45. Wildemeersch D, Janssens D, Pylyser K, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel- releasing intrauterine system: long-term follow-up. Maturitas. 2007;57:210-213.
46. Ørbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol. 2008;111:68-73.
47. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
48. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-613.
49. Andersson K, Mattsson LA, Rybo G, Stadberg E. Intrauterine release of levonorgestrel - a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol. 1992;79:963-967.
50. Riphagen FE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric. 2000;3:199-211.
51. Hampton NR, Rees MC, Lowe DG, Rauramo I, Barlow D, Guillebaud J. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod. 2005;20:2653-2660.
52. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 59, January 2005. Intrauterine device. Obstet Gynecol. 2005;105:223-232.
53. Baldaszti E, Wimmer-Puchinger B, Löschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception. 2003 Feb; 67(2):87-91.
54. Radesic B, Sharma A. Levonorgestrel-releasing intrauterine system for treating menstrual disorders: a patient satisfaction questionnaire. Aust N Z J Obstet Gynaecol. 2004;44:247-251.
55. Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol. 2002;99:608-613.